ImmunOs Therapeutics AG, a Schliren, Switzerland-based bio-technology company and developer of a next generation innate immunity focused immunotherapy platform for cancer, closed a CHF 15M Series A financing.
The round was co-led by venture capital firm BioMedPartners and Pfizer Ventures, with participation from Redalpine, Schroder Adveq, Wille Finance AG, BERNINA BioInvest Ltd alongside new private and existing investors. In conjunction with the financing, ImmunOs Therapeutics has expanded its Board of Directors to include four new members:
– Dr. Markus Hosang of BioMedPartners;
– Dr. Michael Baran of Pfizer Inc.;
– Dr. Reinhard Ambros, former head Novartis Venture Fund; and
– Dr. Daniel Vasella, former Chairman and CEO Novartis.
The company intends to use the funds to complete the first-in-human trials with its lead agent, iosH2, a potential new cancer treatment for both solid and liquid tumors and to broaden its novel immunotherapy iosH platform by advancing additional preclinical programs focusing on both cancer and auto-immunity.
Led by Sean R. Smith, CEO, and Dr. Osiris Marroquin Belaunzaran, CSO and co-founder, ImmunOs Therapeutics is a biotechnology company active in the discovery and development of the next generation of novel human immunomodulatory proteins focused on innate immunity. Its lead program is a novel platform of multitasking biologics targeting diverse immunoregulatory receptors that activate anti-tumor responses.
It is a spin-off company of the University of Zurich and the University of Basel.